Liquid Biopsy in India: The Next Big Step in Early Cancer Detection
In India, more than 70% of cancer cases are diagnosed at Stage 3 or Stage 4 when the disease is significantly harder to treat. A large part of this challenge is the absence of accessible, painless, and repeatable screening tools. Liquid biopsy is changing that, slowly but meaningfully.
Unlike a traditional tissue biopsy, which involves surgery, needles, or sedation, a liquid biopsy is performed on a simple blood sample. It detects molecular signals that cancer cells release into the bloodstream, providing clinicians with critical information about the presence, type, and progression of cancer.
This guide explains what liquid biopsy is, how it works, which patients benefit most, its current availability and cost in India, and what the next few years look like for this technology.
What Is a Liquid Biopsy?
A liquid biopsy is a laboratory test performed on a blood sample (or occasionally urine, saliva, or cerebrospinal fluid) that analyses biological material shed by tumour cells into the body's circulation. The term "liquid biopsy" covers several types of cancer biomarkers, the most clinically significant being circulating tumour DNA (ctDNA).
When cancer cells divide or die, they release small fragments of their DNA into the bloodstream. Advanced genomic sequencing techniques such as next-generation sequencing (NGS) and digital PCR can detect these fragments at extremely low concentrations, identify specific mutations, and draw conclusions about a tumour's characteristics even without a tissue sample.
|
Why It Matters for Indian Patients Traditional tissue biopsies are invasive, expensive, and sometimes not feasible, particularly when tumours are located in hard-to-reach areas (lung, brain, liver). In India, where many patients present late, and repeat biopsies are logistically difficult, liquid biopsy offers a practical alternative for monitoring and treatment guidance. |
Types of Biomarkers Detected by Liquid Biopsy
Different components of tumour material circulate in the blood and serve different clinical purposes. The table below summarises the four main biomarkers and their current and emerging uses:
|
Biomarker |
What It Is |
Clinical Use |
|---|---|---|
|
ctDNA (Circulating Tumour DNA) |
Fragmented tumour DNA is shed into the bloodstream as cancer cells die or divide |
Mutation profiling, treatment selection, monitoring response, detecting minimal residual disease (MRD) |
|
CTCs (Circulating Tumour Cells) |
Whole cancer cells that have broken away from the primary tumour and entered the circulation |
Prognosis in breast, prostate, and colorectal cancer; research into metastatic potential |
|
Exosomes (Extracellular Vesicles) |
Nano-sized vesicles secreted by cancer cells carrying proteins, RNA, and DNA cargo |
Early detection research may carry signals even before ctDNA levels are detectable |
|
miRNA (MicroRNA) |
Small non-coding RNA molecules in circulation; expression patterns differ in cancer |
Emerging biomarker under active clinical investigation for early multi-cancer detection |
Of these, ctDNA is the most clinically validated and most widely used in routine oncology practice in India today. Exosomes and miRNA are primarily in the research phase but show considerable promise for multi-cancer early detection.
How Does a Liquid Biopsy Work? (Step by Step)
-
A blood sample (typically 10–20 mL) is drawn from the patient; no fasting or special preparation is required.
-
The sample is processed to isolate plasma and extract cell-free DNA (cfDNA), which includes both normal DNA and any ctDNA from tumour cells.
-
Advanced genomic techniques, such as NGS, droplet digital PCR (ddPCR), or BEAMing, amplify and sequence the ctDNA fragments.
-
Bioinformatics algorithms compare the tumour-derived sequences against reference databases to identify clinically actionable mutations (EGFR, KRAS, BRAF, ALK, TP53, etc.).
-
A clinical report is generated and reviewed by the oncologist to guide diagnosis, treatment selection, or disease monitoring.
|
Turnaround Time in India Most accredited labs offering liquid biopsy in India (Strand Life Sciences, MedGenome, 4baseCare, Neuberg Diagnostics) return results in 7–14 business days. Turnaround may vary depending on the complexity of the panel ordered. |
Liquid Biopsy vs Tissue Biopsy: Key Differences
Both tests have distinct strengths. They are increasingly used together rather than as substitutes for each other.
|
Factor |
Liquid Biopsy |
Tissue Biopsy |
|---|---|---|
|
Invasiveness |
Non-invasive blood draw only |
Invasive surgical or needle procedure |
|
Risk to the patient |
Negligible, same as a routine blood test |
Bleeding, infection, anaesthesia risks |
|
Tumour heterogeneity |
Captures DNA from multiple tumour sites |
Samples only one tumour location |
|
Repeat testing |
Easy can be repeated every cycle or monthly |
Difficult and risky to repeat frequently |
|
Turnaround time |
Results in 7–14 days at leading labs |
7–21 days, including pathology processing |
|
What it misses |
Cannot pinpoint tumour location or size |
May miss heterogeneous mutations elsewhere |
|
Best suited for |
Monitoring, treatment selection, and MRD detection |
Initial diagnosis, histological confirmation |
|
The Complementary Approach Current oncology guidelines, including those from ESMO and ASCO, recommend using liquid biopsy alongside tissue biopsy rather than replacing it. Tissue biopsy remains the gold standard for initial diagnosis and histological classification. Liquid biopsy is most valuable for treatment selection, monitoring response, detecting resistance mutations, and identifying relapse early. |
Which cancers are liquid biopsy used for in India?
Liquid biopsy is currently available and clinically applied in India for the following cancer types:
-
Non-Small Cell Lung Cancer (NSCLC): ctDNA testing is used to detect EGFR, ALK, ROS1, and KRAS mutations for targeted therapy selection, and to identify acquired resistance mutations (T790M) when treatment stops working.
-
Colorectal Cancer: RAS and BRAF mutation profiling via ctDNA guides anti-EGFR therapy selection. Liquid biopsy also helps monitor for minimal residual disease post-surgery.
-
Breast Cancer: PIK3CA mutations in ctDNA can guide hormonal therapy decisions in ER+ metastatic disease. CTC counts have prognostic value.
-
Hepatocellular Carcinoma (Liver Cancer): ctDNA-based monitoring is increasingly used, given the difficulty of repeated liver biopsies.
-
Prostate Cancer: AR-V7 and other resistance markers in CTCs help determine response to hormonal therapies in castration-resistant prostate cancer.
-
Any MSI-H / dMMR Solid Tumour: ctDNA testing can identify microsatellite instability across tumour types, informing eligibility for pembrolizumab (Keytruda) immunotherapy.
Current Limitations: What Liquid Biopsy Cannot Do
Liquid biopsy is a powerful tool, but it is important to have accurate expectations. Its current limitations include:
-
Very early-stage tumours (Stage 1) may shed insufficient ctDNA, and the sensitivity for reliable detection is lower in early disease
-
It cannot pinpoint the exact location of the tumour or determine tumour size; imaging is still required for this
-
False negatives are possible, particularly in low-burden or slow-growing cancers
-
Results require clinical interpretation; they should never be acted on without specialist review
-
Cost remains a barrier: comprehensive ctDNA panels in India currently range from ₹25,000 to ₹80,000+, depending on the lab and panel breadth
|
The Bottom Line on Limitations A negative liquid biopsy result does not rule out cancer it means no ctDNA was detected at the sensitivity threshold of the test used. Always follow your oncologist's guidance on whether a liquid biopsy result changes your treatment plan. |
Where Can You Get a Liquid Biopsy Done in India?
Liquid biopsy testing is available at specialised oncology centres and commercial genomic diagnostics laboratories across India. Leading providers include:
-
Strand Life Sciences (Bengaluru) comprehensive ctDNA panels and NGS-based tumour profiling
-
MedGenome (Bengaluru, pan-India sample collection) oncology genomics including liquid biopsy
-
4baseCare (Bengaluru) ctDNA testing with clinical interpretation support
-
Neuberg Diagnostics (pan-India) molecular oncology panels including ctDNA
-
Tata Memorial Hospital (Mumbai), AIIMS (Delhi), Kidwai Memorial Institute (Bengaluru) academic centres with in-house genomic platforms
Sample collection for liquid biopsy is often available at local collection centres, with the sample couriered to the central processing laboratory. Confirm NABL accreditation and oncologist acceptance of the lab's reports before ordering.
The Future of Liquid Biopsy in India
The technology is evolving rapidly. Three trends are particularly significant for Indian patients and oncologists:
-
Multi-cancer early detection (MCED) tests: Companies like Grail (Galleri test) and Exact Sciences are developing single blood tests that can screen for 50+ cancer types simultaneously. As these reach India, mass early-detection programmes become feasible.
-
AI-powered interpretation: Machine learning algorithms are improving the accuracy of ctDNA signal detection, reducing false negatives in early-stage disease. AI is also being used to predict tissue of origin from cfDNA methylation patterns.
-
Cost reduction: Indian companies are developing domestic ctDNA platforms targeting ₹10,000–₹15,000 price points, which would make routine monitoring accessible to a much broader patient population.
|
ctDNA in Guiding Immunotherapy Decisions At the AACR Annual Meeting 2025, data from a landmark study showed that ctDNA levels could identify which early-stage, MSI-H cancer patients needed post-surgical immunotherapy and which could safely avoid it. This is a significant development for cancers like colorectal and endometrial cancer in India, where pembrolizumab (Keytruda) is increasingly prescribed. |
Frequently Asked Questions
Is liquid biopsy safe?
Yes. A liquid biopsy requires only a standard blood draw, the same as any routine blood test. There is no surgery, anaesthesia, or recovery time. The risks are negligible and limited to minor bruising at the needle site.
Can a liquid biopsy detect all types of cancer?
Not all cancer types shed ctDNA in detectable quantities, particularly in very early stages. Currently, liquid biopsy is most clinically validated for lung, colorectal, breast, liver, and prostate cancers, as well as any MSI-H/dMMR solid tumour. Multi-cancer early detection tests are under development but not yet routine in India.
Is liquid biopsy a replacement for tissue biopsy?
No, not yet, and not for initial diagnosis. Tissue biopsy remains the gold standard for confirming cancer type and histology. Liquid biopsy is most valuable as a complementary tool for treatment selection, monitoring therapy response, detecting early relapse, and identifying acquired resistance mutations, particularly when repeat tissue sampling is not feasible.
Who should consider a liquid biopsy?
Liquid biopsy is most appropriate for: (1) cancer patients whose tumour is not accessible for a repeat tissue biopsy; (2) patients on targeted therapy where resistance monitoring is needed; (3) patients with MSI-H tumours being evaluated for immunotherapy; and (4) post-surgical patients being monitored for minimal residual disease. It should only be ordered and interpreted by an oncologist.
How much does a liquid biopsy cost in India in 2026?
Comprehensive ctDNA panels range from approximately ₹25,000 to ₹80,000 depending on the laboratory, the breadth of the mutation panel, and whether additional biomarkers (CTCs, methylation) are included. Targeted single-gene ctDNA tests (e.g., EGFR T790M only) may cost less. Costs are expected to decline as domestic Indian platforms scale up.
Is liquid biopsy covered by health insurance in India?
Coverage varies. Some private health insurers include liquid biopsy/molecular profiling under critical illness or oncology riders, particularly for NSCLC and colorectal cancer. Government schemes like Ayushman Bharat PM-JAY do not yet universally cover liquid biopsy, though this is evolving. Always confirm coverage and obtain pre-authorisation before testing.
References:
1. Liquid Biopsies Come of Age: Towards Implementation of Circulating Tumour DNA Wan JCM et al. Nature Reviews Cancer, 2017 https://www.nature.com/articles/nrc.2017.69
2. Current and Future Perspectives of Liquid Biopsies in Genomics-Driven Oncology Heitzer E, Haque IS, Roberts CES, Speicher MR Nature Reviews Genetics, 2019 https://www.nature.com/articles/s41576-018-0071-5
3. Integrating Liquid Biopsies into the Management of Cancer Siravegna G et al. Nature Reviews Clinical Oncology, 2017 https://www.nature.com/articles/nrclinonc.2017.14
4. ctDNA to Guide Immunotherapy After Surgery in MSI-H Cancers AACR Annual Meeting 2025 American Association for Cancer Research (AACR) Cancer Research Catalyst https://www.aacr.org/blog/2025/12/18/cancer-in-2025-funding-new-treatments-and-breakthrough-ideas/
5. ESMO Guidelines: Liquid Biopsy in Clinical Practice European Society for Medical Oncology (ESMO) https://www.esmo.org/guidelines/guidelines-by-topic/esmo-precision-medicine-working-group
6. ASCO Guidelines: Molecular Profiling and Biomarker Testing in Oncology American Society of Clinical Oncology (ASCO) https://www.asco.org/practice-patients/guidelines/oncology-practice
7. Indian Council of Medical Research (ICMR) Cancer Statistics India 2022 Indian Council of Medical Research (ICMR) / National Centre for Disease Informatics and Research https://ncdirindia.org/All_Reports/Report_2022/default.aspx
8. Cell-Free DNA and Circulating Tumour DNA Clinical Applications Review Pantel K, Alix-Panabières C Nature Reviews Genetics, 2019 https://www.nature.com/articles/s41576-019-0140-4
9. Galleri Multi-Cancer Early Detection Test Clinical Validation GRAIL Inc. PATHFINDER Study https://www.nejm.org/doi/full/10.1056/NEJMoa2304213
10. CDSCO Drug Approvals Molecular Diagnostics and Companion Diagnostics in India Central Drugs Standard Control Organisation (CDSCO), Government of India https://cdsco.gov.in
About Apothecare Specialities Pvt Ltd
Apothecare is India's trusted super-speciality pharmacy licensed under the Drugs & Cosmetics Act, 1940, specialising in oncology, antiviral, transplant, anaemia, and rare disease medicines. We deliver pan-India with full cold chain compliance. Visit apothecare.in or call +91 63638 26363.
